RA Capital Healthcare Fund LP, which holds a roughly 10% position and has a director role at Vor Biopharma Inc (NASDAQ:VOR), sold a total of 740,789 shares of Vor common stock for about $11.8 million. The disposition was executed in several blocks between April 13, 2026 and April 15, 2026, with transaction prices ranging from $15.97 to $16.15 per share.
Transaction details show a majority of the shares were sold on April 13, when 530,610 shares traded at an average price of $16.15. On April 14, the fund sold 153,735 shares at an average of $15.97. The schedule concluded on April 15 with a sale of 53,644 shares at an average of $16.01. Following these sales, RA Capital Healthcare Fund LP directly holds 3,197,619 shares of Vor Biopharma.
At the time of the report, Vor Biopharma's stock was trading at $15.60, representing an approximate 47% decline over the preceding six months. Analysis available through InvestingPro noted that the stock appears undervalued relative to its Fair Value estimate and highlighted that the company carries more cash than debt on its balance sheet.
Context on corporate relationships and disclosures
RA Capital Management, L.P. serves as the investment manager for RA Capital Healthcare Fund, L.P. The adviser’s general partner is RA Capital Management GP, LLC, whose managing members are Dr. Peter Kolchinsky and Mr. Rajeev Shah. The adviser, its general partner, the fund and the named individuals disclaim beneficial ownership of the reported securities except to the extent of any pecuniary interest. Separately, Dr. Andrew Levin, who is Partner and Managing Director of the adviser, serves on Vor Biopharma’s board of directors.
Clinical and corporate developments cited
Vor Biopharma has continued to advance its autoimmune program. The company reported dosing the first patient in its global Phase 3 trial for Sjögren’s disease, referred to as UPSTREAM SjD. That study plans to enroll approximately 250 adult patients and will evaluate the efficacy of telitacicept, a therapy licensed from RemeGen.
On the financing and analyst front, the company completed a substantial equity raise of over $330 million, which analysts expect to extend Vor’s financial runway into early fiscal year 2029. Following that raise and revised financing assumptions, Stifel adjusted its price target on Vor to $40 from $55 but maintained a Buy rating. Jefferies initiated coverage with a Buy rating and a $50 price target. H.C. Wainwright kept a Buy stance while trimming its target to $31 from $32. Stifel reiterated its Buy rating at the newly revised $40 target.
Takeaways
The mid-April stock sales by a major shareholder reduced RA Capital Healthcare Fund’s direct holdings but left the firm with a sizeable position in Vor Biopharma. Those transactions occurred while the company pursues late-stage clinical work in autoimmune disease and following a meaningful equity infusion. Analyst coverage remains predominantly positive with varying price targets that reflect differing views on financing assumptions and pipeline potential.
Investors and market participants watching Vor will likely weigh the company’s cash position and debt posture, the outcome of its ongoing Phase 3 Sjögren’s disease trial, and how revised financing assumptions influence valuation benchmarks.